Stalfort John A III — SEC Form 4 filings
SEC reporting owner CIK 1709418. 7 Form 4 filings on record with FilingPulse; latest filed 2026-06-05.
Transaction summary — filings shown
Covers all 7 filings on record, filed 2024-05-31 to 2026-06-05. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 1,123,595 shares.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 14.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | Director | 1 | 1 leg · 1,123,595 sh | — | 3 |
| Taysha Gene Therapies, Inc. (TSHA) | Director | 3 | — | — | 6 |
| Acumen Pharmaceuticals, Inc. (ABOS) | Director | 3 | — | — | 5 |
Form 4 filings — Stalfort John A III
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-05 | 4 | Acumen Pharmaceuticals, Inc. (ABOS) | Grant/award (A): 35,500 @ $0 · Grant/award (A): 53,250 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Taysha Gene Therapies, Inc. (TSHA) | Grant/award (A): 21,335 @ $0 · Grant/award (A): 42,671 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Acumen Pharmaceuticals, Inc. (ABOS) | Grant/award (A): 12,800 @ $0 · Grant/award (A): 19,500 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | Taysha Gene Therapies, Inc. (TSHA) | Grant/award (A): 56,623 @ $0 · Grant/award (A): 113,246 (derivative) @ $0 | EDGAR |
| 2024-11-26 | 4 | Verrica Pharmaceuticals Inc. (VRCA) | Purchase (P): 1,123,595 · Gift (G): 50,000 @ $0 · Purchase (P): 561,797 (derivative) · Purchase (P): 561,797 (derivative) | EDGAR |
| 2024-06-10 | 4 | Acumen Pharmaceuticals, Inc. (ABOS) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-05-31 | 4 | Taysha Gene Therapies, Inc. (TSHA) | Grant/award (A): 49,220 @ $0 · Grant/award (A): 98,440 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1709418 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →